Caris Life Sciences (CAI) Receivables (2024 - 2026)

Caris Life Sciences' Receivables history runs 3 years deep, the most recent figure standing at $94.2 million for Q1 2026.

• In Q1 2026, Receivables changed N/A year-over-year to $94.2 million; the TTM figure through Mar 2026 stood at $94.2 million (changed N/A YoY), while the FY2025 annual figure was $119.3 million, up 28.54% from the prior year.
• Receivables for Q1 2026 stood at $94.2 million, down from $119.3 million in the prior quarter.
• The five-year high for Receivables was $119.3 million in Q4 2025, with the low at $36.6 million in Q3 2025.
• The 3-year median for Receivables is $92.8 million (2024), against an average of $81.0 million.
• Peak annual rise in Receivables reached 28.54% in 2025, while the deepest fall reached 28.54% in 2025.
• Caris Life Sciences' Receivables stood at $92.8 million in 2024, then grew by 28.54% to $119.3 million in 2025, then fell by 21.05% to $94.2 million in 2026.
• Business Quant data shows CAI's Receivables at $94.2 million in Q1 2026, $119.3 million in Q4 2025, and $36.6 million in Q3 2025.